Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report which finds the HIV market, forecast to be worth $11.5 billion in 2016, is set to undergo significant changes.
Last year the HIV market was worth $8 billion. “Commercial Insight: HIV - Reshaping Treatment Paradigms” points out that in the next nine years, patents will expire on key drugs. Simultaneously, there will also be a host of product launches in new and existing classes which will revolutionise treatment of the disease.
The report says Gilead and Bristol-Myers Squibb (BMS), which have the second and third largest HIV market-shares, have collaborated on the first cross-class fixed dose combination, Atripla TM , . Atripla combines all three components of HAART – two nucleoside reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor (NNRTIs) – into a single pill to be taken once each day. First year sales of this new drug reached $174 million in the US alone. Analysts point out that it will be launched in Europe this year and go on to dominate first-line therapy, generating significant sales for Gilead and BMS.
Authors of the report say that the current market leader GlaxoSmithKline (GSK) can expect to see a change in fortune as its ageing HIV portfolio loses patent protection. The company has occupied the greatest portion of the HIV market since the launch of the first antiretroviral, Retrovir in 1997. In 2006, 30% of total antiretroviral sales were made by GSK. This figure, in fact, represented a drop from the previous year’s sales which accounted for 33% of the overall market.
The report identifies GSK's crop of eight marketed products, but points out that at least five are expected to lose patent protection by 2014. Also, majority of the products are relatively old. Taking these factors into account, the report predicts that GSK’s market share could fall sharply unless it finds successful new products.
The study predicts that the sector as a whole is ready to expand and other companies geared up to corner larger market shares. New product launches will change the Highly Active Antiretroviral Therapy (HAART) regimens for both early and late stage therapy. These therapies will simplify early treatment lines and have more convenient dosing schedules, reducing the pill burden on patients to improving their quality of life.
“Commercial Insight: HIV - Reshaping Treatment Paradigms” is available from Report Buyer. For more information go to:
http://www.reportbuyer.com/
Report Buyer product ID: DAT05973
